EML4-ALK变异对ALK阳性肺癌耐药机制与临床结局的影响
该研究回顾性分析129例已知ALK变异的ALK阳性NSCLC患者,并在Foundation Medicine 577例数据集中验证。
要点
- ALK变异3患者耐药突变及G1202R发生率显著高于变异1。
- 变异3与洛拉替尼治疗下更长的无进展生存期相关。
- ALK变异类型可能影响下一代ALK抑制剂的选择。
核心结论
- 特定ALK变异与ALK耐药突变(尤其G1202R)相关,并为变异与临床结局提供分子联系。
- ALK变异是选择下一代ALK抑制剂时潜在的重要考量因素。
研究设计与样本
- 回顾性分析129例已知ALK变异的ALK阳性NSCLC患者。
- 另分析Foundation Medicine数据集中577例ALK阳性NSCLC患者。
主要发现
- 最常见变异为EML4-ALK变异1(55例,43%)和变异3(51例,40%)。
临床怎么用
- 对ALK阳性NSCLC患者可考虑检测ALK变异类型以评估耐药风险。
- 变异3患者可能从洛拉替尼等下一代ALK抑制剂中获益更多。
局限性
- 回顾性研究设计。
- 部分分析基于Foundation Medicine数据库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Advanced anaplastic lymphoma kinase ( ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this association is unknown. Patients and Methods We identified 129 patients with ALK-positive NSCLC with known ALK variants. ALK resistance mutations and clinical outcomes on ALK TKIs were retrospectively evaluated according to ALK variant. A Foundation Medicine data set of 577 patients with ALK-positive NSCLC was also examined. Results The most frequent ALK variants were EML4-ALK variant 1 in 55 patients (43%) and variant 3 in 51 patients (40%). We analyzed 77 tumor biopsy specimens from patients with variants 1 and 3 who had progressed on an ALK TKI. ALK resistance mutations were significantly more common in variant 3 than in variant 1 (57% v 30%; P = .023). In particular, ALK G1202R was more common in variant 3 than in variant 1 (32% v 0%; P < .001). Analysis of the Foundation Medicine database revealed similar associations of variant 3 with ALK resistance mutation and with G1202R ( P = .010 and .015, respectively). Among patients treated with the third-generation ALK TKI lorlatinib, variant 3 was associated with a significantly longer progression-free survival than variant 1 (hazard ratio, 0.31; 95% CI, 0.12 to 0.79; P = .011). Conclusion Specific ALK variants may be associated with the development of ALK resistance mutations, particularly G1202R, and provide a molecular link between variant and clinical outcome. ALK variant thus represents a potentially important factor in the selection of next-generation ALK inhibitors.
引用
- Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018. PMID: 29373100. doi:10.1200/JCO.2017.76.2294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。